Up-Regulated CCDC34 Contributes to the Proliferation and Metastasis of Hepatocellular Carcinoma

References

• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi:10.3322/caac.2126225651787
   PubMed Web of Science ®Google Scholar
• Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604. doi:10.1038/s41575-019-0186-y31439937
   PubMed Web of Science ®Google Scholar
• Xia F, Wu LL, Lau WY, et al. Adjuvant sorafenib after heptectomy for barcelona clinic liver cancer-stage C hepatocellular carcinoma patients. World J Gastroenterol. 2016;22(23):5384–5392. doi:10.3748/wjg.v22.i23.538427340354
   PubMed Web of Science ®Google Scholar
• Burkhard P, Stetefeld J, Strelkov SV. Coiled coils: a highly versatile protein folding motif. Trends Cell Biol. 2001;11(2):82–88. doi:10.1016/S0962-8924(00)01898-511166216
   PubMed Web of Science ®Google Scholar
• Hu X, Zhao Y, Wei L, et al. CCDC178 promotes hepatocellular carcinoma metastasis through modulation of anoikis. Oncogene. 2017;36(28):4047–4059. doi:10.1038/onc.2017.1028319061
   PubMed Web of Science ®Google Scholar
• Tanouchi A, Taniuchi K, Furihata M, et al. CCDC88A, a prognostic factor for human pancreatic cancers, promotes the motility and invasiveness of pancreatic cancer cells. J Exp Clin Cancer Res. 2016;35(1):190. doi:10.1186/s13046-016-0466-027919290
   PubMedGoogle Scholar
• Jiang GY, Zhang XP, Zhang Y, et al. Coiled-coil domain-containing protein 8 inhibits the invasiveness and migration of non-small cell lung cancer cells. Hum Pathol. 2016;56:64–73. doi:10.1016/j.humpath.2016.06.00127342910
   PubMed Web of Science ®Google Scholar
• Gong Y, Qiu W, Ning X, et al. CCDC34 is up-regulated in bladder cancer and regulates bladder cancer cell proliferation, apoptosis and migration. Oncotarget. 2015;6(28):25856–25867. doi:10.18632/oncotarget.v6i2826312564
   PubMedGoogle Scholar
• Qi W, Shao F. Q H. expression of coiled-coil domain containing 34 (CCDC34) and its prognostic significance in pancreatic adenocarcinoma. Med Sci Monit. 2017;23:6012–6018. doi:10.12659/MSM.90795129257799
   PubMed Web of Science ®Google Scholar
• Geng W, Liang W, Fan Y, Ye Z, Zhang L. Overexpression of CCDC34 in colorectal cancer and its involvement in tumor growth, apoptosis and invasion. Mol Med Rep. 2018;17(1):465–473. doi:10.3892/mmr.2017.786029115580
   PubMed Web of Science ®Google Scholar
• Hu DD, Li PC, He YF, Jia W, Hu B. Overexpression of coiled-coil domain-containing protein 34 (CCDC34) and its correlation with angiogenesis in esophageal squamous cell carcinoma. Med Sci Monit. 2018;24:698–705. doi:10.12659/MSM.90833529397026
   PubMed Web of Science ®Google Scholar
• Manning BD, Toker A. AKT/PKB signaling: navigating the network. Cell. 2017;169:381–405. doi:10.1016/j.cell.2017.04.00128431241
   PubMed Web of Science ®Google Scholar
• Nieto MA, Huang RY, Jackson RA, Thiery JP. Emt: 2016. Cell. 2016;166(1):21–45. doi:10.1016/j.cell.2016.06.02827368099
   PubMed Web of Science ®Google Scholar
• Xu Z, Xu M, Liu P, et al. The mTORC2-Akt1 cascade is crucial for c-Myc to promote hepatocarcinogenesis in mice and humans. Hepatology. 2019;70:1600–1613. doi:10.1002/hep.v70.531062368
   PubMed Web of Science ®Google Scholar
• Liu JJ, Li Y, Chen WS, et al. Shp2 deletion in hepatocytes suppresses hepatocarcinogenesis driven by oncogenic beta-catenin, PIK3CA and MET. J Hepatol. 2018;69(1):79–88. doi:10.1016/j.jhep.2018.02.01429505847
   PubMed Web of Science ®Google Scholar
• Bouattour M, Raymond E, Qin S, et al. Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma. Hepatology. 2018;67(3):1132–1149. doi:10.1002/hep.v67.328862760
   PubMed Web of Science ®Google Scholar
• Yang YF, Zhang MF, Tian QH, et al. SPAG5 interacts with CEP55 and exerts oncogenic activities via PI3K/AKT pathway in hepatocellular carcinoma. Mol Cancer. 2018;17(1):117. doi:10.1186/s12943-018-0872-330089483
   PubMed Web of Science ®Google Scholar
• Klingenberg M, Gross M, Goyal A, et al. The long noncoding RNA cancer susceptibility 9 and RNA binding protein heterogeneous nuclear ribonucleoprotein L form a complex and coregulate genes linked to AKT signaling. Hepatology. 2018;68(5):1817–1832. doi:10.1002/hep.v68.529790588
   PubMed Web of Science ®Google Scholar
• Chen Z, Gao W, Pu L, et al. PRDM8 exhibits antitumor activities toward hepatocellular carcinoma by targeting NAP1L1. Hepatology. 2018;68:994–1009. doi:10.1002/hep.2989029572888
   PubMed Web of Science ®Google Scholar
• Vanhaesebroeck B, Stephens L, Hawkins P. PI3K signalling: the path to discovery and understanding. Nat Rev Mol Cell Biol. 2012;13(3):195–203. doi:10.1038/nrm329022358332
   PubMed Web of Science ®Google Scholar
• Pauta M, Rotllan N, Fernandez-Hernando A, et al. Akt-mediated foxo1 inhibition is required for liver regeneration. Hepatology. 2016;63(5):1660–1674. doi:10.1002/hep.v63.526473496
   PubMed Web of Science ®Google Scholar
• Wu SY, Lan SH, Liu HS. Degradative autophagy selectively regulates CCND1 (cyclin D1) and MIR224, two oncogenic factors involved in hepatocellular carcinoma tumorigenesis. Autophagy. 2019;15(4):729–730. doi:10.1080/15548627.2019.156991830646811
   PubMed Web of Science ®Google Scholar
• Chen RW, Bemis LT, Amato CM, et al. Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma. Blood. 2008;112(3):822–829. doi:10.1182/blood-2008-03-14218218483394
   PubMed Web of Science ®Google Scholar
• Chan TH, Chen L, Liu M, et al. Translationally controlled tumor protein induces mitotic defects and chromosome missegregation in hepatocellular carcinoma development. Hepatology. 2012;55(2):491–505. doi:10.1002/hep.2470921953552
   PubMed Web of Science ®Google Scholar
• Otto T, Sicinski P. Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer. 2017;17:93–115. doi:10.1038/nrc.2016.13828127048
   PubMed Web of Science ®Google Scholar
• Pradella D, Naro C, Sette C, Ghigna C. EMT and stemness: flexible processes tuned by alternative splicing in development and cancer progression. Mol Cancer. 2017;16(1):8. doi:10.1186/s12943-016-0579-228137272
   PubMedGoogle Scholar
• Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3ʹ kinase/AKT pathways. Oncogene. 2005;24(50):7443–7454. doi:10.1038/sj.onc.120909116288291
   PubMed Web of Science ®Google Scholar
• Rafael D, Doktorovova S, Florindo HF, et al. EMT blockage strategies: targeting Akt dependent mechanisms for breast cancer metastatic behaviour modulation. Curr Gene Ther. 2015;15(3):300–312. doi:10.2174/156652321566615012612364225619882
   PubMed Web of Science ®Google Scholar